About GH Research
GH Research (NASDAQ:GHRS) is a biopharmaceutical company dedicated to transforming the treatment landscape for psychiatric and neurological disorders. Its innovative research focuses on developing and testing novel therapies, with a particular emphasis on 5-MeO-DMT, a psychedelic compound with potential therapeutic benefits. The company's projects span various stages of clinical development, aiming to address unmet medical needs in mental health care. GH Research's objectives include advancing its pipeline through rigorous clinical trials, ensuring the safety and efficacy of its therapies, and ultimately making these innovative treatments accessible to patients in need. With a commitment to scientific excellence and patient well-being, GH Research strives to lead the way in psychedelic and neurological research.
Snapshot
Operations
Produtos e/ou serviços de GH Research
- Development of a novel 5-MeO-DMT therapy for treatment-resistant depression, focusing on a unique inhalation approach.
- Expanding the pipeline to explore treatments for other psychiatric and neurological disorders using psychedelic-based therapies.
- Advancement of proprietary drug delivery systems to enhance therapeutic efficacy and patient experience.
- Conducting rigorous clinical trials to ensure safety and effectiveness of their psychedelic-based treatments.
- Collaboration with healthcare professionals to integrate their therapies into broader treatment paradigms.
- Innovating on formulations and dosing mechanisms to allow for personalized treatment approaches.
equipe executiva do GH Research
- Mr. Florian Schonharting M.Sc. (Econ)Co-Founder & Non-Executive Chairman of the Board
- Dr. Velichka Valcheva M.D., M.Sc.Chief Executive Officer
- Mr. Magnus HalleCo-Founder & MD of Ireland
- Ms. Julie Ryan F.C.A.Vice President of Finance
- Mr. Aaron Cameron M.B.A.Chief Operating Officer